Pharmacokinetics, Pharmacodynamics, and Safety of Plozasiran in Subjects With Renal or Hepatic Impairment

Jennifer HellawellVP of Clinical Development, Arrowhead Pharmaceuticals

“Patients living with extremely high triglycerides often suffer from significant comorbidities. Today's data represent an important step in bridging the gap between patient needs and scientific innovation. As a physician at heart, I'm proud to be part of the team advancing next-generation therapies for this underserved community. We're excited to have better characterized the PK and PD of plozasiran in this potentially broader patient population. These data bring us closer to delivering meaningful impact for patients.”